JP2007513967A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513967A5
JP2007513967A5 JP2006544002A JP2006544002A JP2007513967A5 JP 2007513967 A5 JP2007513967 A5 JP 2007513967A5 JP 2006544002 A JP2006544002 A JP 2006544002A JP 2006544002 A JP2006544002 A JP 2006544002A JP 2007513967 A5 JP2007513967 A5 JP 2007513967A5
Authority
JP
Japan
Prior art keywords
inhibitor
tyrosine kinase
kit
receptor tyrosine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006544002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/041333 external-priority patent/WO2005058341A2/en
Publication of JP2007513967A publication Critical patent/JP2007513967A/ja
Publication of JP2007513967A5 publication Critical patent/JP2007513967A5/ja
Withdrawn legal-status Critical Current

Links

JP2006544002A 2003-12-11 2004-12-09 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 Withdrawn JP2007513967A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52861703P 2003-12-11 2003-12-11
PCT/US2004/041333 WO2005058341A2 (en) 2003-12-11 2004-12-09 Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases

Publications (2)

Publication Number Publication Date
JP2007513967A JP2007513967A (ja) 2007-05-31
JP2007513967A5 true JP2007513967A5 (https=) 2008-01-31

Family

ID=34699881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006544002A Withdrawn JP2007513967A (ja) 2003-12-11 2004-12-09 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物

Country Status (4)

Country Link
US (1) US20050171182A1 (https=)
EP (1) EP1699477A2 (https=)
JP (1) JP2007513967A (https=)
WO (1) WO2005058341A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302771T1 (de) * 2001-12-27 2005-09-15 Theravance Inc Indolinon-derivative als protein-kinasehemmer
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20130210034A1 (en) * 2005-11-04 2013-08-15 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
WO2008076394A1 (en) * 2006-12-14 2008-06-26 Tautatis, Inc. Compositions and methods for the treatment of cancer
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
US9867825B2 (en) * 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
JP6267619B2 (ja) * 2014-09-30 2018-01-24 学校法人近畿大学 慢性骨髄性白血病の治療用組成物
US11633401B2 (en) 2018-07-06 2023-04-25 Memorial Sloan Kettering Cancer Center Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (https=) * 1986-04-11 1989-02-04 Hoechst India
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6150359A (en) * 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
NZ503788A (en) * 1997-10-27 2002-11-26 Agouron Pharma 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6242196B1 (en) * 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CA2349832A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
EP1144372B1 (en) * 1999-01-13 2005-11-30 Warner-Lambert Company Llc Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
CA2355470C (en) * 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
GB9910579D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
WO2001044247A2 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
EP1339702A1 (en) * 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
GB0007371D0 (en) * 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
EP1295878B1 (en) * 2000-06-30 2004-09-15 Banyu Pharmaceutical Co., Ltd. Pyrazinone derivatives
DZ3401A1 (fr) * 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
ES2230337T3 (es) * 2000-09-01 2005-05-01 Glaxo Group Limited Derivados de oxindol.
TR200401316T4 (tr) * 2000-09-29 2004-07-21 Eli Lilly And Company Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
US20020197691A1 (en) * 2001-04-30 2002-12-26 Myriad Genetics, Incorporated FLT4-interacting proteins and use thereof
US6756374B2 (en) * 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US7223388B2 (en) * 2001-08-03 2007-05-29 Board Of Regents, The Univeristy Of Texas System Modified reoviral therapy
ES2269793T3 (es) * 2001-10-30 2007-04-01 Novartis Ag Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
CA2466762A1 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
ATE302771T1 (de) * 2001-12-27 2005-09-15 Theravance Inc Indolinon-derivative als protein-kinasehemmer
ES2251677T3 (es) * 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
EP1467968A1 (en) * 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DOP2003000556A (es) * 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
SG2013013339A (en) * 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1482944A4 (en) * 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20040136975A1 (en) * 2002-03-22 2004-07-15 Duesbery Nicholas S Anthrax lethal factor inhibits tumor growth and angiogenesis
JP4588447B2 (ja) * 2002-08-09 2010-12-01 セラヴァンス， インコーポレーテッド 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof

Similar Documents

Publication Publication Date Title
Meng et al. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development: D. Meng, RD Carvajal
Laird et al. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents
Sun et al. Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl) methylidenyl] indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases
JP6250671B2 (ja) 免疫関連及び炎症性疾患の治療
Reungwetwattana et al. Targeted therapies in development for non-small cell lung cancer
TWI569799B (zh) 抑制組成型活性磷酸化ｆｌｔ３激酶的方法
JP2007513967A5 (https=)
Maris et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
AU2021327130A1 (en) Bicycle conjugates specific for Nectin-4 and uses thereof
JP2020532556A5 (https=)
KR20170110145A (ko) N-(3,5-디메톡시페닐)-n'-(1-메틸에틸)-n-[3-(1-메틸-1h-피라졸-4-일)퀴녹살린-6-일]에탄-1,2-디아민을 포함하는 제약 조성물
JP2007515400A5 (https=)
Ahmed et al. Signal transduction in the chronic leukemias: implications for targeted therapies
Izzedine et al. Sunitinib malate
Ling et al. Protein kinase inhibitors for acute leukemia
Xue et al. Recent developments and advances of FGFR as a potential target in cancer
González-Muñoz et al. The need for new treatments targeting MPNST: the potential of strategies combining MEK inhibitors with antiangiogenic agents
JP7650243B2 (ja) 上皮組織の慢性炎症性傷害、化生、異形成、及びがんを治療するための方法ならびに組成物
Mologni Development of RET kinase inhibitors for targeted cancer therapy
JP2009508960A5 (https=)
Hashemi-Sadraei et al. Targeting FGFR in squamous cell carcinoma of the lung
Haber et al. Translating cancer genomics for precision oncology in biliary tract cancers
Seki et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones
CA3113468A1 (en) Grapiprant unit dosage forms
US20230056604A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer